Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000504033 | SCV000597134 | uncertain significance | not specified | 2016-03-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764052 | SCV000895006 | uncertain significance | Fanconi anemia complementation group P | 2022-04-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001203560 | SCV001374733 | uncertain significance | Fanconi anemia | 2023-12-30 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1462 of the SLX4 protein (p.Ala1462Ser). This variant is present in population databases (rs138484365, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with SLX4-related conditions. ClinVar contains an entry for this variant (Variation ID: 436778). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV000764052 | SCV002096988 | uncertain significance | Fanconi anemia complementation group P | 2022-01-11 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Sema4, |
RCV001203560 | SCV002529351 | uncertain significance | Fanconi anemia | 2021-10-21 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002524298 | SCV003615531 | uncertain significance | Inborn genetic diseases | 2024-04-20 | criteria provided, single submitter | clinical testing | The c.4384G>T (p.A1462S) alteration is located in exon 12 (coding exon 11) of the SLX4 gene. This alteration results from a G to T substitution at nucleotide position 4384, causing the alanine (A) at amino acid position 1462 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |